Teligent

105 Lincoln Avenue
Buena
New Jersey
08310
United States

Tel: (856) 697-1441

Show jobs for this employer

About Teligent

We develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada.

We are a dynamic group of about 200 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Our Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. 

Our Quality, Regulatory Affairs and Operations colleagues work closely with our Product Development team to achieve regulatory approval in the countries where we operate. Our Commercial team sells our portfolio of topical medicines and hospital-based sterile injectable products.

We are energized about what we are going to accomplish at Teligent today. We believe in taking ownership, driving execution, and making smart, quick decisions.

We are passionate about our science, and are committed to building a diverse pipeline of topical, injectable, complex and ophthalmic projects.It’s a powerful, uniting force that magnifies what we could do on our own. The Teligent spark empowers us to dream of a brighter future. To envision our work having a deeper impact on others’ lives. To build something that is bigger than ourselves.

Our journey is underway. It is driven by our culture, which is a reflection of our people.

NASDAQ: TLGT

80 articles with Teligent

  • Teligent, Inc. announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented.

  • Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the first quarter of 2021 and provided a business update.

  • Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31, 2021 financial results and business update. Conference Call Information Date: Tuesday, May 25, 2021 Time: 8:30 a.m. Eastern Time

  • Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2020.

  • Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021.

  • Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors

  • Generic Pharmaceutical and Contract Manufacturing Industry Leader Joins Teligent Board, Effective Immediately

  • Completes $77 million debt-for-equity exchange with Series C noteholders and senior secured lenders at premiums of 60% and 30% to the 5 day VWAP

  • Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission.

  • Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.

  • Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November 25, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

  • Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020 and adjourned to November 11, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

  • Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approve

  • Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senior Notes due 2023 (the “New 2023 Notes”) in exchange for approximately $57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 4.75% Convertible Seni

  • Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020. Financial Highlights Second Quarter 2020 vs. First Quarter 2020 Revenues of $13.6 million, an increase of $6.1 million or 82%, stronger demand for both US topical products and injectable products sold in Canada   Gross profit of $2.5 million, an increase of $3.7 mill

  • Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19 th , 2020 to discuss the 2 nd quarter 2020 financial results and business update. The Company invites you to listen to the call by dialing (866) 393-8366.  International participants should call (409) 350-3154.  Participants should ask to join the Teligent, Inc. call. This ca

  • Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent's Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests. Mr. Celentano joined Tel

  • Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Convertible Notes due 2023 (the “New 2023 Notes”). After taking into account an original issue discount and other transaction fees (including fees payable to the purchasers in the form of additional New 2023 Notes), the Com

  • Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16, 2020. Timothy B. Sawyer, President and CEO of the Company, commented, “We are pleased that Phil has agreed to join our Teligent team.  Phil’s extensive experience as a general counsel/chief legal and

  • Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that it received notice from The NASDAQ Stock Market LLC on June 18, 2020 indicating that the Company has regained compliance with NASDAQ Listing Rule 5450, which requires the Company’s common stock to maintain a minimum bid price of $1.00 per share.